Phase 3 Hypertension Trial, Recruiting NCT06643819 Sponsor: Chong Kun Dang Pharmaceutical Condition: Hypertension
Back to Hypertension

Phase 3 Hypertension Trial, Recruiting

NCT06643819
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 19 years old or older.
  • People who have chosen to take part willingly and have signed a consent form.

Who may not be able to join:

  • People who have, or are suspected to have, high blood pressure caused by another underlying medical condition (called secondary hypertension).
  • People who have a condition where their blood pressure drops significantly when they stand up (orthostatic hypotension).
  • People who need to take blood pressure medications other than the ones being tested in this trial.
  • People who have type 1 diabetes, or whose diabetes is not well controlled.
  • People who have taken part in another clinical trial and received an experimental drug within the 4 weeks before their screening visit.
  • People who have had a problem with drug or alcohol misuse, or are suspected of having one, within the 24 weeks before their screening visit.
  • Women who are pregnant or breastfeeding, or people who do not agree to use a suitable method of contraception during the trial and for two weeks after taking the last dose of the trial drug.
  • People who the trial doctor considers unsuitable to participate for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-2-2194-0479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Chong Kun Dang Pharmaceutical
Registry
ClinicalTrials.gov
Start date
14 October 2024
Est. completion
31 March 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

change from baseline in MASBP(Mean Ambulatory Systolic Blood Pressure)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov